EMA Hails Success Of COVID-19 Multi-Regulator Collaboration
Executive Summary
The international COVID-19 collaborative assessment pilot, OPEN, helped regulators to reach broadly similar conclusions on vaccines and therapeutics and to avoid differences in labeling. However, most experts involved agreed there was room for improvement in some areas, particularly gaps between submissions to the different regulators.
You may also be interested in...
EU Joint Regulatory Assessment Project Bears Fruit In COVID-19
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.